Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Sequential BCMA- and GPRC5D-targeted bispecific antibody therapy in multiple myeloma: Real-world outcomes and first report of dual bispecific antibody-refractory patients

View Full Paper
Ask AI
Bookmark
Share

Authors

SSSamantha ShenoyJWJeffrey L. WolfTMThomas G. Martin

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows bispecific antibody therapy effectiveness in multiple myeloma, indicating high need for dual refractory patient data.

Key Points

  • Characterize real-world outcomes of sequential BCMA and GPRC5D-targeted bispecific antibody therapy in multiple myeloma patients.
  • Conducted a retrospective study at UCSF on RRMM patients treated with teclistamab or talquetamab.
  • Collected patient, disease, and treatment characteristics descriptively.
  • Performed multivariate analyses using Cox regression for survival outcomes.
  • 121 RRMM patients received SOC teclistamab or talquetamab treatment.
  • Overall response rate (ORR) with BsAb1 was 81.0%, with median PFS of 17.1 months.
  • 22 patients relapsed on both BCMA and GPRC5D BsAbs with a median OS of 7.5 months.

Cite This Study

Shenoy et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e014https://doi.org/10.1182/blood-2025-5760
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world response and toxicity profiles of sequential bispecific antibody therapies in Relapsed/Refractory multiple myeloma2025
  2. 2Real-world comparison of anti-GPRC5D bispecific therapy versus anti-BCMA treatment in relapsed/refractory multiple myeloma after prior BCMA-directed therapy.2026
  3. 3Impact of previous BCMA exposure: Evidence from practice outside of clinical trials to inform talquetamab sequencing2025
  4. 4Bispecific antibodies in the treatment of relapsed refractory multiple myeloma: A meta analysis.2026
  5. 5Evolving real-world uptake and patient characteristics of bispecific antibodies in Relapsed/Refractory multiple myeloma: Insights from a US community oncology network2025